Claudio Pasquali

Claudio Pasquali

Associate Professor

Telefono: +39 338 9336513

Phone lab: 049 8218832


9/11/1978: Degree in Medicina e Chirurgia (M.D.) - University of Padua
10/7/1984: Postgraduate Degree in General Surgery – University of Padua
19/12/1988: Postgraduate Degree in Gastroenterology an Digestive Endoscopy – University of Padua.
04/11/1991: Postgraduate Degree in Endocrine Surgery – University of Verona

12/04/81- 28/03/82  Research Assistant – Dept. Medicine/Endocrine Unit - Royal Postgraduate Medical School - l'Hammersmith Hospital – University of London (U.K.)21/10/1992  Ricercatore Universitario Confermato (Assistant Professor) in General Surgery – University of Padua 01/10/2006 – current:  Associate Professor in General Surgery – University of Padua

Research assistant in the gastrointestinal hormones Lab. (Prof. S.R. Bloom) at the Hammersmith Hospital - London (1981-2), then was responsable in charge of a research laboratory at the University of Padua involved in investigations on gastrointestinal hormones, glucose methabolism of pancreatic cancer, role of tumor markers in exocrine and endocrine pancreatic neoplasms. Clinical research included diagnosis of pancreatic endocrine and exocrine tumors, intraoperative diagnosis, medical, surgical therapy of pancreatic and periampullary diseases, and gastrointestinal neuroendocrine tumors. The interest for neuroendocrine GI tumors, led to collect the largest italian series of these patients (more than 500 cases). Contributed to several multicentric national and international trials on diagnosis and surgical therapy of pancreatic diseases and to draw Italian guidelines for acute pancreatitis, chronic pancreatitis and cystic pancreatic neoplasms and reference pathway for diagnosis of Neuroendocrine Tumors and Pancreatic Cancer for the Veneto Region.
Invited speaker or chairman in international meetings of several surgical societies (IHPBA, EASS etc.) on pancreatic endocrine tumors or tumor markers. Member of many scientific societies (IHPBA, EPC, EDS, ISS/SIC) included the International Ass.of Endocrine Surgeons and European Association of Endocrine Surgeons.

Member of the Council of AISP (Italian Society for the study of the pancreas) from 1999 to 2002 and from 2011 to 2014, Member of the Scientific Board of the Italian Chapter of I.H.P.B.A from 1999 to 2002, and Council Member of the European Pancreatic Club (E.P.C.) from 2005 to 2008.

From 2012 Principal Investigator and Head of a Research Unit in the PANcreatic Disease ReseArch (PANDoRA) consortium (Heidelberg /Germany) for investigations on molecular biology and genetics of pancreatic diseases. 

Principal Investigator and Head of a Research Unit in the National Research Project  (1999 to 2000): G.I. Neuroendocrine Tumors: Relationship between gene alteration and prognosis.

Principal Investigator and Head of a Research Unit in the National Research Project     (2001 to 2002): G.I. Neuroendocrine Tumors: Tumor growth control.

Principal Investigator and Head of a Research Unit in the National Research Project  (2003 to 2004): G.I. Neuroendocrine Tumors. Molecular basis for the diagnosis and treatment.

Principal Investigator and Head of a Research Unit in the National Research Project (2006 to 2007): Neuroendocrine Lung neoplasms (Carcinoids) and Gastro-entero-pancreatici (GEP): clinical, immunophenotypical and molecular characterization to define prognosis and therapeutic approach.

Author of more than 850 scientific contributions including original papers in international journals, book chapters, oral comunications in internationals and national congresses.

1. Sperti C., PASQUALI C., Guolo P., Polverosi R., Liessi G., Pedrazzoli S.: Serum tumor markers and cyst fluid analysis are useful for the diagnosis of pancreatic cystic tumors. Cancer 78: 237-43, 1996.

2. PASQUALI C., Rubello D., Sperti C., Gasparoni P., Liessi G., Chierichetti F., Ferlin G., Pedrazzoli S.: Neuroendocrine tumor imaging: can 18-FDG Positron Emission Tomography detect tumors with poor prognosis and aggressive behavior? World J Surg 22: 588-592, 1998

3. Sperti C., PASQUALI C., Chierichetti F., Liessi G., Ferlin G., Pedrazzoli S.: Value of 18-fluorodeoxyglucose positron emission tomography in the patients with cystic tumors of the pancreas. Ann Surg 234: 675-80, 2001.

4. PASQUALI C., Sperti C., Filipponi C., Pedrazzoli S.: Epidemiology of pancreatic cancer in Northeastern Italy: incidence, resectability rate, hospital stay, costs and survival (1990-1992). Digest Liver Dis 34: 723-31, 2002.

5. Sperti C., Bissoli S., PASQUALI C., Frison L., Liessi G., Chierichetti F., Pedrazzoli S.: 18-Florodeoxyglucose positron emission tomography enhances computed tomography diagnos of malignant intraductal papillary mucinous neoplasms of the pancreas. Ann Surg 246:932-939,2007.

6. Pedrazzoli S., Sperti C., PASQUALI C., Bissoli S., Chierichetti F.: Comparison of International Consensus Guidelines Versus 18-Fdg PET in Detecting Malignancy of Intraductal Papillary Mucinous Neoplasms of the Pancreas. Ann Surg  254:971-976,2011

7. Moletta L., Milanetto A.C., Vincenzi V., Alaggio R., Pedrazzoli S., PASQUALI C.: Pancreatic Secondary Lesions from Renal Cell Carcinoma. World J Surg 38(11):3002-3006 , 2014 doi:10.1007/s00268-014-2672-2

8. Childs E.J., Mocci E., Campa D., Bracci P.M., Gallinger S., Goggins M., Li D., Neale R.E., Olson S.H., Scelo G., Amundadottir L.T., Bamlet W.R., Bijlsma M.F., Blackford A., Borges M., Brennan P., Brenner H., Bueno-de-Mesquita H.B., Canzian F., Capurso G., Cavestro G.M., Chaffee K.G., Chanock S.J., Cleary S.P., Cotterchio M., Foretova L., Fuchs C., Funel N., Gazouli M., Hassan M., Herman J.M., Holcatova I., Holly E.A., Hoover R.N., Hung R.J., Janout V., Key T.J., Kupcinskas J., Kurtz R.C., Landi S., Lu L., Malecka-Panas E., Mambrini A., Mohelnikova-Duchonova B., Neoptolemos J.P., Oberg A.L., Orlow I., PASQUALI C., Pezzilli R., Rizzato C., Saldia A., Scarpa A., Stolzenberg-Solomon R.Z., Strobel O., Tavano F., Vashist Y.K., Vodicka P., Wolpin B.M., Yu H., Petersen G.M., Risch H.A., Klein A.P.: Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. Nat Genet 47(8):911-6, 2015 doi: 10.1038/ng.3341

9. Partelli S., Tamburrino D., Lopez C., Albers M., Milanetto A.C., PASQUALI C., Manzoni M., Toumpanakis C., Fusai G., Bartsch D., Falconi M.: Active Surveillance versus surgery of non-functioning pancreatic neuroendocrine neoplasms <2 cm. in MEN1 patients. Neuroendocrinology 103(6):779-86, 2016. doi: 10.1159/000443613

10. Obazee O., Capurso G., Tavano F., Archibugi L., De Bonis., Greenhalf W., Key T., PASQUALI C, Milanetto A.C., Hackert T., Fogar P., Liço V., Dervenis C., Lawlor R.T., Landoni L., Gazouli M., Zambon C.F., Funel N., Strobel O., Jamroziak K., Cantù C., Malecka-Panas E., Landi S., Neoptolemos J.P., Basso D., Talar-Wojnarowska R., Rinzivillo M., Andriulli A., Canzian F., Campa D.: Common genetic variants associated with pancreatic adenocarcinoma may also modify risk of pancreatic neuroendocrine neoplasms. Carcinogenesis 39(3):360-367, 2018. doi: 10.1093/carcin/bgx150.

Ipsen S.p.A. 2017: Euro 15.000 (Research Grant)
Private 2017 : Euro 5.000 (for Research)